Although China has made significant progress in brain-computer interface (BCI) technology in recent years—with numerous universities, research institutes, and startups actively entering the field—mass production and widespread commercialization remain distant goals. Most current BCI research in China is still confined to laboratory settings, primarily focusing on invasive or semi-invasive systems that face technical bottlenecks in signal acquisition accuracy, device stability, and long-term biocompatibility. While non-invasive devices offer higher safety and easier deployment, their lower signal resolution limits their applicability in complex scenarios. Additionally, the lack of industry standards, an underdeveloped regulatory framework, and lengthy clinical validation processes further hinder the transition from prototypes to market-ready products. Although some companies have launched early-stage applications targeting medical rehabilitation or attention monitoring, systemic challenges persist in cost control, user adaptability, data security, and ethical compliance. Experts generally agree that the next 5–10 years will be critical for technological maturation and ecosystem development, and truly consumer-grade BCI products are unlikely to reach mass production without interdisciplinary collaboration and supportive policies.
尽管近年来国内脑机接口（BCI）技术取得显著进展，多家高校、科研机构和初创企业纷纷布局该领域，但距离真正实现大规模量产和商业化应用仍有不小差距。当前，国内脑机接口研究多集中于实验室阶段，主要聚焦于侵入式或半侵入式系统，在信号采集精度、设备稳定性、长期生物相容性等方面仍面临技术瓶颈。此外，非侵入式设备虽安全性高、易于部署，但信号分辨率较低，难以满足复杂应用场景的需求。与此同时，行业标准缺失、监管体系不完善、临床验证周期长等问题也制约了产品从原型走向市场。虽然部分企业已推出面向医疗康复、注意力监测等特定场景的早期产品，但整体来看，脑机接口在成本控制、用户适配性、数据安全与伦理规范等方面仍需系统性突破。专家普遍认为，未来5-10年将是技术积累与生态构建的关键期，真正的消费级脑机接口产品要实现量产，仍需跨学科协同与政策支持。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/8869.html